Teva launches a generic version of Elidel in the USA

31 December 2018

Teva Pharmaceutical Industries (NYSE: TEVA) has launched a generic version of Elidel (pimecrolimus) Cream, 1% in the USA.

Pimecrolimus Cream, 1% is a topical prescription medicine to be used as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis) in non-immuno-compromised adults and children two years of age and older who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.

Elidel was originated by Novartis (NOVN: VX) but, in 2011, the Swiss pharma giant assigned global rights manufacture and market the eczema treatment to Swedish drugmaker Meda (OMX: MEDA A). Elidel was approved in the USA in 2001 and in the European Union in 2002.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK